Key Points
- CEO Barry Balfe sold 5,175 shares for about $1.07 million, reducing his direct stake by 35.77% to 9,291 shares. The sale covered tax withholding obligations tied to vested equity awards.
- ICON reported quarterly EPS of $2.66, slightly above the $2.62 consensus, and revenue of $2.02 billion, also ahead of expectations; revenue was down 0.9% year over year.
- Analysts’ consensus rating was Moderate Buy, with an average price target of $213.76.
Icon Plc (NASDAQ:ICLR - Get Free Report) CAO Emer Lyons sold 264 shares of the business's stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $206.66, for a total transaction of $54,558.24. Following the completion of the transaction, the chief accounting officer owned 1,217 shares in the company, valued at $251,505.22. This represents a 17.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Emer Lyons also recently made the following trade(s):
- On Friday, October 23rd, Emer Lyons sold 272 shares of Icon stock. The shares were sold at an average price of $182.37, for a total transaction of $49,604.64.
Icon Stock Performance
NASDAQ:ICLR opened at $203.77 on Wednesday. The firm has a 50-day moving average of $173.23 and a two-hundred day moving average of $146.72. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.32 and a quick ratio of 1.32. The stock has a market cap of $15.60 billion, a P/E ratio of 35.07, a PEG ratio of 11.53 and a beta of 1.19. Icon Plc has a 1-year low of $66.57 and a 1-year high of $219.04.
Icon (NASDAQ:ICLR - Get Free Report) last announced its earnings results on Tuesday, October 27th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.62 by $0.04. Icon had a return on equity of 7.73% and a net margin of 5.45%. The business had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same period in the previous year, the company earned $3.31 earnings per share. The company's revenue for the quarter was down .9% compared to the same quarter last year. On average, research analysts expect that Icon Plc will post 9.57 earnings per share for the current fiscal year.
Analyst Ratings Changes
ICLR has been the topic of a number of recent analyst reports. Citigroup upped their target price on Icon from $175.00 to $215.00 and gave the company a "neutral" rating in a research report on Thursday, October 29th. Truist Financial raised their price target on shares of Icon from $209.00 to $268.00 and gave the stock a "buy" rating in a research report on Thursday, October 29th. BMO Capital Markets restated an "outperform" rating and issued a $235.00 price target on shares of Icon in a research note on Thursday, October 29th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $254.00 price target on shares of Icon in a report on Thursday, October 29th. Finally, Robert W. Baird upped their price target on shares of Icon from $210.00 to $249.00 and gave the company an "outperform" rating in a report on Thursday, October 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Icon presently has a consensus rating of "Moderate Buy" and an average target price of $213.76.
Check Out Our Latest Research Report on ICLR
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of ICLR. GAMMA Investing LLC increased its position in Icon by 21.4% in the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company's stock valued at $68,000 after acquiring an additional 69 shares during the period. Bank Julius Baer & Co. Ltd Zurich boosted its position in shares of Icon by 0.4% during the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 20,762 shares of the medical research company's stock valued at $3,529,000 after purchasing an additional 79 shares in the last quarter. Grove Bank & Trust grew its position in Icon by 30.0% in the second quarter. Grove Bank & Trust now owns 866 shares of the medical research company's stock worth $150,000 after buying an additional 200 shares during the last quarter. Buckhead Capital Management LLC grew its position in Icon by 0.9% in the third quarter. Buckhead Capital Management LLC now owns 25,591 shares of the medical research company's stock worth $4,350,000 after buying an additional 218 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Icon in the third quarter valued at $38,000. 95.61% of the stock is owned by institutional investors and hedge funds.
About Icon
(
Get Free Report)
ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.
Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
